Area of research
Radiology, Nuclear Medicine and Imaging · Cancer Research
Research interest
Research interests include MRI in cancer diagnosis, Radiomics and Machine Learning in Medical Imaging, Advanced Neuroimaging Techniques and Applications, and Advanced MRI Techniques and Applications.
Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI
The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker
The <scp>ISMRM</scp> Open Science Initiative for Perfusion Imaging (<scp>OSIPI</scp>): Results from the <scp>OSIPI–Dynamic Contrast‐Enhanced</scp> challenge
Associations of Multiparametric Breast MRI Features, Tumor-Infiltrating Lymphocytes, and Immune Gene Signature Scores Following a Single Dose of Trastuzumab in HER2-Positive Early-Stage Breast Cancer
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial
Imaging for Response Assessment in Cancer Clinical Trials
Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702)
Diffusion-weighted MRI for Unenhanced Breast Cancer Screening
Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702)
Background parenchymal enhancement on breast MRI: A comprehensive review
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial
Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
Diffusion-weighted breast MRI: Clinical applications and emerging techniques
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis